Antimicrobial susceptibility of Stenotrophomonas maltophilia from United States medical centers 2019 through 2023
We evaluated the antimicrobial susceptibility of 1,400 clinical isolates of Stenotrophomonas maltophilia consecutively collected from United States medical centers in 2019 through 2023. Aztreonam-avibactam was the most active compound, followed by trimethoprim-sulfamethoxazole, minocycline, and levofloxacin. Aztreonam-avibactam retained potent activity against isolates not susceptible to trimethoprim-sulfamethoxazole, minocycline, and/or levofloxacin.